Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Fineline Cube May 7, 2026
Company

Innovent Biologics Reports Over RMB 2 Billion in Q2 2024 Sales, Highlighting 50% YOY Growth

Fineline Cube Aug 9, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has reported a significant...

Company Medical Device

Sansure Biotech’s MTHFR Gene Detection Kit Receives NMPA Approval, Aids in Pregnancy Health Management

Fineline Cube Aug 9, 2024

Sansure Biotech Inc. (SHA: 688289), a specialist in molecular diagnostics based in China, has achieved...

Company Drug

Huadong Medicine Expands Global Footprint with Launch of Aesthetic Injection MaiLi in Singapore

Fineline Cube Aug 9, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced the international expansion...

Company Deals

Harbour BioMed Reclaims Rights to HBM7008 as Cullinan Therapeutics Cancels Licensing Deal

Fineline Cube Aug 9, 2024

Harbour BioMed (HBM), a biopharmaceutical company with operations in the Netherlands, the United States, and...

Company Deals R&D

Wondfo Biotech and University of Science, Malaysia Deepen Ties with Formal Partnership

Fineline Cube Aug 9, 2024

Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a biotechnology firm based in China, has formalized...

Company Drug

WestGene Biopharma’s EB Virus-Targeting mRNA Vaccine WGc-043 Clears for Clinical Trials in China

Fineline Cube Aug 9, 2024

WestGene Biopharma Co., Ltd., a biotechnology company based in Chengdu, has received approval from the...

Company Deals

Hansoh Pharmaceutical Secures Rights to Lupeng’s BTK Inhibitor LP-168 in Licensing Deal

Fineline Cube Aug 9, 2024

Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...

Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns Orphan Drug Designation from FDA for Small-Cell Lung Cancer

Fineline Cube Aug 9, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company

Novo Nordisk Reports 25% YOY Sales Growth in H1 and Q2 2024, Led by GLP-1 Drugs

Fineline Cube Aug 9, 2024

Novo Nordisk (NYSE: NVO), a Danish pharmaceutical giant specializing in diabetes care, has reported its...

Company Legal / IP

Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement

Fineline Cube Aug 9, 2024

Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO:...

Company Deals

WuXi Biologics Partners with Medigene for TCR TCE Development in Refractory Tumors

Fineline Cube Aug 9, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development and Manufacturing Organization (CRDMO) in China,...

Company

Eli Lilly & Co. Resolves Manufacturing Constraints, Reports 37% YOY Sales Growth in Q2 2024

Fineline Cube Aug 9, 2024

Eli Lilly & Co. (NYSE: LLY), a prominent pharmaceutical company based in the U.S., has...

Company Deals

AI-Driven Drug Firms Recursion and Exscientia to Merge in a Deal Valued at Approximately USD 850 Million

Fineline Cube Aug 9, 2024

Recursion (NASDAQ: RXRX), a U.S.-based clinical-stage TechBio company, and Exscientia plc (NASDAQ: EXAI), a U.K.-headquartered...

Company

Viatris Inc. Reports 2% Operational Growth in Q2’24, Driven by Generics and Brands

Fineline Cube Aug 9, 2024

Viatris Inc. has announced its financial results for the second quarter of 2024, highlighting approximately...

Company Drug

Insilico Medicine’s ISM6331 Earns FDA Orphan Drug Designation for Mesothelioma Treatment

Fineline Cube Aug 8, 2024

Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...

Company

BeiGene’s Q2 2024 Revenues Surge 56% YOY, Highlighted by Strong U.S. Market Performance

Fineline Cube Aug 8, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has reported its financial results for the second...

Company

Betta Pharmaceuticals Reports Strong H1 2024 Revenue Growth and Advances in Drug Development

Fineline Cube Aug 8, 2024

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has reported its financial results...

Policy / Regulatory

NHSA Preliminary Review Identifies Potential NRDL Additions, Including Novel Therapies and ADCs

Fineline Cube Aug 8, 2024

The National Healthcare Security Administration (NHSA) has released a preliminary list of drugs that have...

Company Digital R&D

Shanghai Pharmaceuticals’ SH-INNO Incubator to Drive Biopharmaceutical Innovation and Collaboration

Fineline Cube Aug 8, 2024

Shanghai Pharmaceuticals (SPH;HKG: 2607; SHA: 601607) has launched the “SH-INNO incubator,” a collaborative initiative with...

Company Deals Hospital

Hygeia Healthcare Holdings Acquires Chang An Hospital in Deal Valued at RMB 1.66 Billion

Fineline Cube Aug 8, 2024

Hygeia Healthcare Holdings Co., Ltd, a Shanghai-based medical investment and healthcare group, has announced the...

Posts pagination

1 … 311 312 313 … 661

Recent updates

  • Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations
  • BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year
  • Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio
  • Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients
  • Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations

Company

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Company Drug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.